| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cooking | 6 | 2023 | 70 | 2.700 |
Why?
|
| Meals | 4 | 2020 | 64 | 2.170 |
Why?
|
| Proteasome Inhibitors | 8 | 2017 | 238 | 2.170 |
Why?
|
| Lactones | 7 | 2016 | 93 | 2.120 |
Why?
|
| Oxidative Stress | 13 | 2019 | 1157 | 2.050 |
Why?
|
| Apoptosis | 41 | 2018 | 7855 | 1.880 |
Why?
|
| Nutritional Status | 4 | 2021 | 353 | 1.860 |
Why?
|
| Histone Deacetylase Inhibitors | 8 | 2018 | 627 | 1.800 |
Why?
|
| Pyrroles | 7 | 2016 | 592 | 1.630 |
Why?
|
| Adamantane | 7 | 2018 | 21 | 1.580 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 4 | 2015 | 34 | 1.580 |
Why?
|
| Hydroquinones | 7 | 2018 | 33 | 1.580 |
Why?
|
| Histone Demethylases | 4 | 2020 | 145 | 1.520 |
Why?
|
| Reactive Oxygen Species | 19 | 2019 | 1012 | 1.480 |
Why?
|
| Cancer Survivors | 6 | 2022 | 740 | 1.440 |
Why?
|
| Feeding Behavior | 3 | 2020 | 826 | 1.330 |
Why?
|
| Diet Therapy | 2 | 2019 | 53 | 1.230 |
Why?
|
| Leukemia | 8 | 2019 | 1722 | 1.190 |
Why?
|
| Glioma | 4 | 2024 | 1969 | 1.150 |
Why?
|
| Diet | 7 | 2024 | 1489 | 1.140 |
Why?
|
| Exercise Therapy | 4 | 2023 | 290 | 1.120 |
Why?
|
| Glutathione | 6 | 2020 | 377 | 1.110 |
Why?
|
| Fusion Proteins, bcr-abl | 10 | 2015 | 1144 | 1.040 |
Why?
|
| Pediatric Obesity | 3 | 2020 | 377 | 0.990 |
Why?
|
| DNA Fragmentation | 8 | 2018 | 208 | 0.940 |
Why?
|
| Brain Stem Neoplasms | 2 | 2024 | 102 | 0.890 |
Why?
|
| Hydroxamic Acids | 4 | 2015 | 459 | 0.880 |
Why?
|
| NADPH Oxidases | 2 | 2015 | 145 | 0.870 |
Why?
|
| Health Education | 4 | 2022 | 303 | 0.870 |
Why?
|
| Neoplasms | 16 | 2023 | 15848 | 0.870 |
Why?
|
| Protease Inhibitors | 5 | 2011 | 214 | 0.860 |
Why?
|
| Glioblastoma | 5 | 2016 | 1776 | 0.850 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 99 | 0.830 |
Why?
|
| Anthracyclines | 3 | 2021 | 339 | 0.810 |
Why?
|
| Benzamides | 8 | 2018 | 1883 | 0.770 |
Why?
|
| Oxidation-Reduction | 9 | 2019 | 718 | 0.770 |
Why?
|
| Health Promotion | 3 | 2023 | 511 | 0.760 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2024 | 7240 | 0.760 |
Why?
|
| Antineoplastic Agents | 13 | 2024 | 14681 | 0.720 |
Why?
|
| Parents | 4 | 2020 | 1064 | 0.720 |
Why?
|
| Brain Neoplasms | 5 | 2020 | 4982 | 0.700 |
Why?
|
| Heme Oxygenase-1 | 2 | 2011 | 59 | 0.660 |
Why?
|
| Carotenoids | 1 | 2020 | 101 | 0.660 |
Why?
|
| Neoplastic Stem Cells | 5 | 2015 | 1469 | 0.640 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2017 | 603 | 0.640 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 444 | 0.630 |
Why?
|
| Child | 21 | 2024 | 30462 | 0.630 |
Why?
|
| Family | 2 | 2019 | 762 | 0.620 |
Why?
|
| Dietary Proteins | 1 | 2019 | 255 | 0.610 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2012 | 2633 | 0.600 |
Why?
|
| Caspases | 14 | 2016 | 701 | 0.600 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2015 | 66 | 0.580 |
Why?
|
| Community Health Services | 1 | 2018 | 129 | 0.580 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2018 | 2900 | 0.560 |
Why?
|
| Humans | 87 | 2024 | 271144 | 0.560 |
Why?
|
| Boronic Acids | 3 | 2015 | 367 | 0.560 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2015 | 5413 | 0.550 |
Why?
|
| Pyridines | 2 | 2018 | 1312 | 0.540 |
Why?
|
| Acetylcysteine | 2 | 2015 | 139 | 0.540 |
Why?
|
| Survivors | 4 | 2016 | 1025 | 0.530 |
Why?
|
| Cell Proliferation | 8 | 2015 | 7299 | 0.530 |
Why?
|
| Ubiquitin | 1 | 2017 | 337 | 0.520 |
Why?
|
| Pyrazines | 3 | 2015 | 525 | 0.510 |
Why?
|
| Up-Regulation | 4 | 2011 | 2465 | 0.510 |
Why?
|
| Caspase 8 | 4 | 2011 | 151 | 0.500 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 958 | 0.490 |
Why?
|
| Steroids | 1 | 2016 | 376 | 0.480 |
Why?
|
| Blast Crisis | 3 | 2012 | 587 | 0.480 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 164 | 0.470 |
Why?
|
| Calcium Signaling | 2 | 2009 | 284 | 0.460 |
Why?
|
| Energy Intake | 1 | 2016 | 525 | 0.450 |
Why?
|
| Counseling | 1 | 2016 | 384 | 0.450 |
Why?
|
| Tumor Cells, Cultured | 14 | 2015 | 5835 | 0.440 |
Why?
|
| Histone Deacetylases | 4 | 2020 | 366 | 0.430 |
Why?
|
| Animals | 33 | 2024 | 62874 | 0.420 |
Why?
|
| Membrane Glycoproteins | 3 | 2015 | 1109 | 0.420 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 2373 | 0.410 |
Why?
|
| ErbB Receptors | 3 | 2020 | 2379 | 0.410 |
Why?
|
| Hospitals, Pediatric | 1 | 2017 | 793 | 0.400 |
Why?
|
| Signal Transduction | 3 | 2024 | 12207 | 0.400 |
Why?
|
| Parenting | 1 | 2016 | 353 | 0.400 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2009 | 2474 | 0.400 |
Why?
|
| Child Nutrition Disorders | 1 | 2012 | 78 | 0.400 |
Why?
|
| Heart Diseases | 2 | 2015 | 737 | 0.390 |
Why?
|
| Adolescent | 15 | 2023 | 32621 | 0.380 |
Why?
|
| Lymphoma | 1 | 2019 | 1516 | 0.380 |
Why?
|
| Cardiotoxicity | 3 | 2023 | 161 | 0.370 |
Why?
|
| Epigenesis, Genetic | 5 | 2024 | 1432 | 0.370 |
Why?
|
| Chromatin | 3 | 2024 | 1050 | 0.360 |
Why?
|
| Cladribine | 2 | 2002 | 253 | 0.350 |
Why?
|
| K562 Cells | 5 | 2012 | 345 | 0.350 |
Why?
|
| Mice | 19 | 2024 | 35999 | 0.340 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2007 | 1344 | 0.340 |
Why?
|
| Antioxidants | 6 | 2015 | 521 | 0.340 |
Why?
|
| Health Behavior | 4 | 2020 | 597 | 0.340 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 1986 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2015 | 4956 | 0.330 |
Why?
|
| Heart | 2 | 2018 | 1211 | 0.330 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 14871 | 0.330 |
Why?
|
| Indoles | 1 | 2015 | 1035 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2426 | 0.330 |
Why?
|
| Philadelphia Chromosome | 1 | 2013 | 834 | 0.330 |
Why?
|
| Nitrophenols | 1 | 2009 | 95 | 0.320 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2023 | 744 | 0.310 |
Why?
|
| Response Elements | 1 | 2009 | 200 | 0.310 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2024 | 841 | 0.310 |
Why?
|
| Bortezomib | 4 | 2016 | 553 | 0.310 |
Why?
|
| Piperazines | 6 | 2009 | 2153 | 0.300 |
Why?
|
| Body Mass Index | 3 | 2020 | 2238 | 0.300 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 192 | 0.300 |
Why?
|
| Feasibility Studies | 3 | 2018 | 2347 | 0.300 |
Why?
|
| Sarcoma | 3 | 2023 | 1840 | 0.300 |
Why?
|
| Doxorubicin | 4 | 2023 | 3140 | 0.300 |
Why?
|
| Jurkat Cells | 4 | 2015 | 319 | 0.290 |
Why?
|
| Cysteine Endopeptidases | 2 | 1998 | 266 | 0.280 |
Why?
|
| Glucocorticoids | 4 | 1999 | 628 | 0.280 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2013 | 1372 | 0.270 |
Why?
|
| Nutritional Support | 2 | 2020 | 79 | 0.270 |
Why?
|
| Health Status | 3 | 2023 | 626 | 0.270 |
Why?
|
| Cytochrome c Group | 3 | 2002 | 74 | 0.260 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 7464 | 0.260 |
Why?
|
| Blotting, Western | 6 | 2015 | 3650 | 0.260 |
Why?
|
| Acetylation | 4 | 2016 | 519 | 0.260 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 630 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 720 | 0.250 |
Why?
|
| Parent-Child Relations | 2 | 2019 | 266 | 0.240 |
Why?
|
| Quality of Life | 2 | 2016 | 4725 | 0.240 |
Why?
|
| Vegetables | 3 | 2023 | 330 | 0.240 |
Why?
|
| Drug Synergism | 6 | 2011 | 1369 | 0.230 |
Why?
|
| Pyrimidines | 6 | 2009 | 3667 | 0.230 |
Why?
|
| Imatinib Mesylate | 6 | 2015 | 1691 | 0.230 |
Why?
|
| ARNTL Transcription Factors | 1 | 2024 | 52 | 0.230 |
Why?
|
| Histones | 4 | 2020 | 1511 | 0.230 |
Why?
|
| Sucrose | 1 | 2024 | 67 | 0.230 |
Why?
|
| Quinones | 1 | 2003 | 24 | 0.230 |
Why?
|
| Tranylcypromine | 2 | 2015 | 9 | 0.230 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 25 | 0.230 |
Why?
|
| Gardening | 1 | 2023 | 12 | 0.220 |
Why?
|
| Mutation | 5 | 2024 | 15856 | 0.220 |
Why?
|
| Male | 15 | 2020 | 128590 | 0.220 |
Why?
|
| Female | 16 | 2020 | 148642 | 0.220 |
Why?
|
| Enzyme Activation | 6 | 2013 | 1837 | 0.210 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 3658 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2009 | 1547 | 0.210 |
Why?
|
| DNA Damage | 3 | 2011 | 1980 | 0.210 |
Why?
|
| Life Style | 2 | 2018 | 615 | 0.210 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2000 | 95 | 0.200 |
Why?
|
| Egtazic Acid | 1 | 2002 | 61 | 0.200 |
Why?
|
| Body Weight | 2 | 2019 | 1337 | 0.200 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 2214 | 0.200 |
Why?
|
| Fruit | 2 | 2022 | 301 | 0.200 |
Why?
|
| Immunoblotting | 3 | 2015 | 917 | 0.190 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2001 | 72 | 0.190 |
Why?
|
| Azacitidine | 1 | 2007 | 1215 | 0.190 |
Why?
|
| Mice, SCID | 3 | 2019 | 1857 | 0.180 |
Why?
|
| Inhalation Exposure | 1 | 2020 | 46 | 0.180 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 243 | 0.180 |
Why?
|
| Caspase 3 | 3 | 2013 | 483 | 0.180 |
Why?
|
| Smoke | 1 | 2020 | 61 | 0.180 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 3417 | 0.180 |
Why?
|
| Granulocytes | 1 | 2001 | 243 | 0.180 |
Why?
|
| Taste | 1 | 2020 | 53 | 0.180 |
Why?
|
| Cells, Cultured | 7 | 2015 | 5785 | 0.180 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 555 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2021 | 113 | 0.170 |
Why?
|
| Endopeptidases | 2 | 1999 | 233 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2016 | 551 | 0.170 |
Why?
|
| Nutritional Sciences | 1 | 2020 | 68 | 0.170 |
Why?
|
| Diet Surveys | 1 | 2020 | 119 | 0.170 |
Why?
|
| Meat | 1 | 2020 | 93 | 0.170 |
Why?
|
| Islets of Langerhans | 1 | 2001 | 245 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2009 | 1922 | 0.170 |
Why?
|
| Etoposide | 2 | 2001 | 906 | 0.170 |
Why?
|
| Adenosine Triphosphate | 1 | 2002 | 601 | 0.170 |
Why?
|
| Immunoprecipitation | 2 | 2012 | 594 | 0.170 |
Why?
|
| Pteridines | 1 | 2019 | 35 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2020 | 123 | 0.170 |
Why?
|
| Cell Death | 2 | 2001 | 689 | 0.170 |
Why?
|
| Mitochondria | 4 | 2002 | 1319 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 16601 | 0.160 |
Why?
|
| Superoxides | 2 | 2009 | 222 | 0.160 |
Why?
|
| Child, Preschool | 4 | 2020 | 17011 | 0.160 |
Why?
|
| Lysine | 1 | 2020 | 428 | 0.160 |
Why?
|
| Video Recording | 1 | 2020 | 276 | 0.150 |
Why?
|
| Texas | 2 | 2020 | 6420 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 1836 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2018 | 104 | 0.150 |
Why?
|
| Schools | 1 | 2019 | 236 | 0.150 |
Why?
|
| Mice, Nude | 5 | 2021 | 4360 | 0.150 |
Why?
|
| Multienzyme Complexes | 1 | 1998 | 231 | 0.150 |
Why?
|
| Recreation | 1 | 2017 | 23 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 1955 | 0.150 |
Why?
|
| Autoantibodies | 1 | 2001 | 599 | 0.140 |
Why?
|
| Lymphocytes | 3 | 2006 | 1274 | 0.140 |
Why?
|
| Cerebellum | 1 | 2001 | 476 | 0.140 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 117 | 0.140 |
Why?
|
| Internet | 1 | 2021 | 698 | 0.140 |
Why?
|
| Exercise | 3 | 2023 | 1211 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 10702 | 0.140 |
Why?
|
| Receptors, Notch | 1 | 2019 | 377 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2017 | 129 | 0.130 |
Why?
|
| Adult | 10 | 2023 | 81619 | 0.130 |
Why?
|
| Cell Line | 4 | 2019 | 5440 | 0.130 |
Why?
|
| Nucleoproteins | 1 | 2016 | 38 | 0.130 |
Why?
|
| Qualitative Research | 1 | 2019 | 623 | 0.130 |
Why?
|
| Self Report | 1 | 2020 | 792 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 337 | 0.130 |
Why?
|
| NADPH Oxidase 2 | 1 | 2015 | 43 | 0.130 |
Why?
|
| Phosphatidylserines | 3 | 2002 | 73 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2018 | 613 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 2474 | 0.130 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2016 | 204 | 0.130 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2015 | 39 | 0.130 |
Why?
|
| Cell Cycle | 2 | 2012 | 2151 | 0.120 |
Why?
|
| RNA Interference | 2 | 2019 | 1398 | 0.120 |
Why?
|
| Child Behavior | 1 | 2017 | 249 | 0.120 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 216 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 2471 | 0.120 |
Why?
|
| Cell Survival | 4 | 2015 | 3082 | 0.120 |
Why?
|
| Hydrogen Peroxide | 2 | 2009 | 225 | 0.120 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 504 | 0.120 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 215 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 922 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 2618 | 0.120 |
Why?
|
| Adiposity | 1 | 2016 | 238 | 0.120 |
Why?
|
| Dasatinib | 2 | 2015 | 881 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2015 | 153 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2003 | 3352 | 0.110 |
Why?
|
| Eating | 1 | 2016 | 449 | 0.110 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2016 | 294 | 0.110 |
Why?
|
| Weight Loss | 1 | 2017 | 637 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2019 | 2854 | 0.110 |
Why?
|
| Cerebellar Neoplasms | 1 | 2018 | 487 | 0.110 |
Why?
|
| Proteolysis | 1 | 2015 | 380 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2015 | 635 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2001 | 852 | 0.110 |
Why?
|
| Cell Size | 1 | 2012 | 145 | 0.100 |
Why?
|
| Medulloblastoma | 1 | 2018 | 587 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 154 | 0.100 |
Why?
|
| Overweight | 1 | 2016 | 484 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2018 | 728 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 908 | 0.100 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 163 | 0.100 |
Why?
|
| Onium Compounds | 1 | 2011 | 9 | 0.100 |
Why?
|
| Flow Cytometry | 4 | 2015 | 3083 | 0.100 |
Why?
|
| Prognosis | 4 | 2023 | 22467 | 0.100 |
Why?
|
| Obesity | 2 | 2016 | 2941 | 0.100 |
Why?
|
| Risk Factors | 3 | 2016 | 17838 | 0.100 |
Why?
|
| Ethyldimethylaminopropyl Carbodiimide | 1 | 2011 | 6 | 0.100 |
Why?
|
| Deoxycytidine Kinase | 2 | 2002 | 27 | 0.100 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2013 | 190 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 5902 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2001 | 1079 | 0.100 |
Why?
|
| Research Design | 1 | 2019 | 1568 | 0.100 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2011 | 19 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 9079 | 0.100 |
Why?
|
| Psychometrics | 1 | 2016 | 963 | 0.090 |
Why?
|
| Razoxane | 1 | 2010 | 22 | 0.090 |
Why?
|
| Rats | 2 | 2015 | 6661 | 0.090 |
Why?
|
| Iron Chelating Agents | 1 | 2010 | 33 | 0.090 |
Why?
|
| Patient Preference | 1 | 2013 | 222 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 47 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1215 | 0.090 |
Why?
|
| Intracellular Membranes | 2 | 2002 | 117 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3919 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 2125 | 0.090 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 191 | 0.090 |
Why?
|
| Acute Disease | 1 | 2015 | 2522 | 0.090 |
Why?
|
| Myocytes, Cardiac | 1 | 2015 | 705 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2023 | 2906 | 0.090 |
Why?
|
| Actins | 1 | 2013 | 615 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2019 | 5838 | 0.090 |
Why?
|
| Membrane Potentials | 2 | 2002 | 464 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2012 | 304 | 0.090 |
Why?
|
| Genomic Instability | 1 | 2012 | 522 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1379 | 0.090 |
Why?
|
| Necrosis | 1 | 2011 | 605 | 0.090 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 184 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 757 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1089 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2010 | 336 | 0.080 |
Why?
|
| Stereoisomerism | 1 | 2009 | 178 | 0.080 |
Why?
|
| Topotecan | 1 | 2009 | 248 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2017 | 1463 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3497 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 1567 | 0.080 |
Why?
|
| Pediatrics | 1 | 2017 | 1183 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 1 | 2009 | 193 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 935 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 2670 | 0.070 |
Why?
|
| Astrocytes | 1 | 2011 | 405 | 0.070 |
Why?
|
| Young Adult | 5 | 2023 | 22071 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2009 | 6494 | 0.070 |
Why?
|
| Transfection | 3 | 2009 | 3173 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 360 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2019 | 9436 | 0.070 |
Why?
|
| Infant | 2 | 2019 | 13950 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2016 | 6027 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2009 | 815 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2399 | 0.070 |
Why?
|
| Clone Cells | 2 | 2005 | 592 | 0.070 |
Why?
|
| Middle Aged | 3 | 2020 | 90072 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2012 | 1669 | 0.070 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 703 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 487 | 0.070 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2003 | 233 | 0.070 |
Why?
|
| Telomere | 2 | 2000 | 534 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1934 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 2267 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 3655 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5161 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 2335 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2009 | 1719 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2020 | 33842 | 0.060 |
Why?
|
| Biomarkers | 3 | 2023 | 5108 | 0.060 |
Why?
|
| Calcium | 2 | 2002 | 1645 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 1312 | 0.060 |
Why?
|
| Thiazoles | 1 | 2009 | 729 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2008 | 582 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2019 | 13354 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3543 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2011 | 2438 | 0.060 |
Why?
|
| Buthionine Sulfoximine | 1 | 2003 | 42 | 0.060 |
Why?
|
| Macrophages | 2 | 2002 | 1369 | 0.060 |
Why?
|
| Troponin | 1 | 2023 | 92 | 0.060 |
Why?
|
| Phagocytosis | 2 | 2002 | 297 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2003 | 2126 | 0.050 |
Why?
|
| Tyrphostins | 1 | 2003 | 112 | 0.050 |
Why?
|
| DNA | 2 | 2024 | 3076 | 0.050 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2002 | 29 | 0.050 |
Why?
|
| Thapsigargin | 1 | 2002 | 43 | 0.050 |
Why?
|
| Genes, bcl-2 | 2 | 2000 | 176 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2013 | 1742 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1269 | 0.050 |
Why?
|
| Staurosporine | 1 | 2002 | 150 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2012 | 4192 | 0.050 |
Why?
|
| Deoxycytosine Nucleotides | 1 | 2001 | 32 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 15260 | 0.050 |
Why?
|
| Genes, MDR | 1 | 2001 | 42 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 388 | 0.050 |
Why?
|
| Chelating Agents | 1 | 2002 | 134 | 0.050 |
Why?
|
| fas Receptor | 1 | 2002 | 201 | 0.050 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2002 | 143 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2001 | 63 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2011 | 2736 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2007 | 2035 | 0.050 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2001 | 126 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 1437 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2001 | 157 | 0.050 |
Why?
|
| Oxidants | 1 | 2000 | 51 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2021 | 39722 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 3658 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2001 | 168 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 594 | 0.040 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 1999 | 27 | 0.040 |
Why?
|
| Developed Countries | 1 | 2020 | 44 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 3398 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2003 | 1962 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2001 | 214 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 9046 | 0.040 |
Why?
|
| Disease Progression | 1 | 2010 | 6897 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2002 | 494 | 0.040 |
Why?
|
| Pulmonary Emphysema | 1 | 2020 | 156 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 579 | 0.040 |
Why?
|
| Models, Biological | 2 | 2013 | 3227 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2001 | 666 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2003 | 994 | 0.040 |
Why?
|
| Phagocytes | 1 | 1997 | 43 | 0.040 |
Why?
|
| Apolipoproteins | 1 | 1997 | 72 | 0.040 |
Why?
|
| Cytarabine | 2 | 2001 | 2014 | 0.040 |
Why?
|
| Caspase 1 | 1 | 1997 | 63 | 0.040 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1997 | 92 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1999 | 472 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 912 | 0.040 |
Why?
|
| Heart Failure | 1 | 2010 | 2498 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 1468 | 0.030 |
Why?
|
| Cell Division | 1 | 2001 | 2718 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1999 | 916 | 0.030 |
Why?
|
| Proteins | 2 | 2002 | 2049 | 0.030 |
Why?
|
| Oncogenes | 1 | 2019 | 700 | 0.030 |
Why?
|
| DNA Repair | 1 | 2024 | 1886 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2021 | 1600 | 0.030 |
Why?
|
| Endonucleases | 1 | 1996 | 183 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 4510 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 2838 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 791 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2009 | 451 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2021 | 949 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1998 | 1136 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 626 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1999 | 896 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1997 | 797 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 1737 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2009 | 2109 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 1999 | 1377 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 30937 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 4774 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 326 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2000 | 2023 | 0.030 |
Why?
|
| Adenosine | 1 | 2015 | 300 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 704 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 1604 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 1303 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 2 | 2009 | 1599 | 0.030 |
Why?
|
| Caspase 9 | 2 | 2003 | 192 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2006 | 4988 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2011 | 44 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2002 | 262 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2013 | 579 | 0.020 |
Why?
|
| Paclitaxel | 1 | 1999 | 2099 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 2 | 1999 | 5233 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 824 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 738 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1998 | 1734 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 2562 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 1999 | 7938 | 0.020 |
Why?
|
| Neurons | 1 | 2001 | 2465 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 504 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2009 | 157 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2029 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1999 | 2955 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2002 | 380 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 340 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 2674 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2011 | 736 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2009 | 354 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 191 | 0.020 |
Why?
|
| Transduction, Genetic | 2 | 1999 | 497 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 747 | 0.020 |
Why?
|
| Aged | 1 | 2013 | 73178 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 401 | 0.020 |
Why?
|
| Protein Biosynthesis | 2 | 2002 | 1037 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2000 | 5042 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 5113 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 7218 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2006 | 286 | 0.020 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2006 | 121 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 10354 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 2500 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 1999 | 1757 | 0.020 |
Why?
|
| Tyrosine | 1 | 2006 | 510 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 3459 | 0.010 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2003 | 26 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2009 | 1045 | 0.010 |
Why?
|
| Dimerization | 1 | 2003 | 318 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 281 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 2002 | 48 | 0.010 |
Why?
|
| Phosphatidylethanolamines | 1 | 2002 | 63 | 0.010 |
Why?
|
| Catalase | 1 | 2002 | 75 | 0.010 |
Why?
|
| Ion Transport | 1 | 2002 | 77 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 302 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2002 | 318 | 0.010 |
Why?
|
| Serpins | 1 | 2002 | 74 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2002 | 207 | 0.010 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2002 | 124 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7951 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 6467 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 2648 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2002 | 270 | 0.010 |
Why?
|
| Glutaredoxins | 1 | 2001 | 34 | 0.010 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2000 | 28 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 687 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2002 | 336 | 0.010 |
Why?
|
| Sulfhydryl Reagents | 1 | 1999 | 13 | 0.010 |
Why?
|
| Annexin A5 | 1 | 1999 | 75 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 887 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 885 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2001 | 340 | 0.010 |
Why?
|
| Metaphase | 1 | 1999 | 124 | 0.010 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 1999 | 32 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 1460 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 860 | 0.010 |
Why?
|
| Polyploidy | 1 | 1999 | 78 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1999 | 457 | 0.010 |
Why?
|
| CHO Cells | 1 | 1999 | 323 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 696 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1997 | 16 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 7818 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2000 | 385 | 0.010 |
Why?
|
| Cricetinae | 1 | 1999 | 792 | 0.010 |
Why?
|
| Chromosomes | 1 | 1999 | 323 | 0.010 |
Why?
|
| Phospholipids | 1 | 1997 | 172 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1997 | 310 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 1667 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1996 | 228 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 200 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1999 | 960 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 4646 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 1539 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 6793 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1998 | 1510 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 2315 | 0.010 |
Why?
|
| Vidarabine | 1 | 1996 | 1383 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 4182 | 0.010 |
Why?
|
| Time Factors | 1 | 1999 | 13131 | 0.000 |
Why?
|